Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101
December 19, 2024 12:50 ET
|
Vittoria Biotherapeutics
Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria’s proprietary Senza5 platform that...
Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies
December 09, 2024 06:30 ET
|
Vittoria Biotherapeutics
Data further validates the Company’s proprietary Senza5™ technology platform to engineer enabled CAR-T cell therapies PHILADELPHIA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics,...
Vittoria Biotherapeutics Announces Oral and Poster Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
November 25, 2024 08:00 ET
|
Vittoria Biotherapeutics
PHILADELPHIA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat...
Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates
November 12, 2024 06:30 ET
|
Vittoria Biotherapeutics
Funding to support clinical proof-of-concept for the lead program, VIPER-101 PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company...
Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology
July 22, 2024 08:00 ET
|
Vittoria Biotherapeutics
PHILADELPHIA, July 22, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, announces a recent publication by investigators at the University of Pennsylvania in...
Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer
April 16, 2024 08:00 ET
|
Vittoria Biotherapeutics
PHILADELPHIA, April 16, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced that Keith Westby has joined the company as its inaugural Chief...
Vittoria Biotherapeutics Announces Appointment of Life Sciences Veteran Rosemary Mazanet, M.D., Ph.D. as Chief Medical Officer
February 27, 2024 08:00 ET
|
Vittoria Biotherapeutics
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced today that accomplished life sciences leader, Rosemary Mazanet, M.D.,...
Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma
December 07, 2023 08:00 ET
|
Vittoria Biotherapeutics
VIPER-101 is an autologous, CD5 knock-out CAR-T therapy for the treatment of T-cell lymphoma Initiating first-in-human Phase 1 trial in H1 of 2024 PHILADELPHIA, Dec. 07, 2023 (GLOBE NEWSWIRE) --...
Vittoria Biotherapeutics Announces the Presentation of New Data Supporting the Company's Platform at the 65th American Society of Hematology Annual Meeting
November 29, 2023 08:00 ET
|
Vittoria Biotherapeutics
PHILADELPHIA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics announced the presentations of abstracts authored by researchers at the University of Pennsylvania and a poster authored by...
Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies
November 14, 2023 08:00 ET
|
Vittoria Biotherapeutics
PHILADELPHIA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics today announced it has secured over $15 million in a private financing round. The funds will be used to continue advancing...